Without adequate protein intake and strength training, GLP-1s can lead to loss of lean mass along with fat
M. Jzwiak, M. Bauer, W. Kamysz, and P. Kleczkowska, Multifunctionality and Possible Medical Application of the BPC 157 PeptideLiterature and Patent Review, MDPI AG, Jan. 2025. doi: 10.3390/ph18020185
Key Takeaways Gynecomastia, affecting 35% of men, is often caused by hormonal imbalances and can persist after substantial weight loss, such as semaglutide (Wegovy), a medication which reduces appetite and body weight, but may not affect the glandular breast tissue characteristic of the condition
FDA shared a post on LinkedIn : The FDA is proposing to exclude semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which identifies bulk drug substances that outsourcing facilities may use in compounding when there is a clinical need
The disadvantage is the rounding required at lower doses
Although it addresses three metabolic pathways and supports weight and other health metrics, no medication acts in a vacuum